Gates gives Selecta $1.25M for malaria vax; Protein Sciences extends contract for Flublok;

> The Bill & Melinda Gates Foundation has granted Selecta Biosciences $1.25 million to advance work on a new malaria vaccine. Story

> Protein Sciences has extended its contract with BARDA, grabbing $50.6 million to support development, scale-up and expanded licensure of flu vaccines Flublok and Panblok. Release

> Vietnam will add pneumonia, diarrhea and HPV vaccines to its subsidized national program. Story

> AmVac has initiated a Phase III trial of lead vaccine Gynevac for bacterial vaginosis. Release

> PsiOxus Therapeutics has initiated a Phase I/II trial to test its oncolytic vaccine enadenotucirev in ovarian cancer patients. Release

> Jack Marsh has resigned from Novavax' ($NVAX) board of directors and will become director emeritus. Release

> TapImmune ($TPIV) has appointed Dr. Keith Knutson to chair its scientific advisory board. Release

And Finally... Czech scientists have developed a new vaccine against Lyme disease that's ready to use on animals and could be available for humans in the future. Story

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.